Alzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
Another anti-amyloid antibody treatment for Alzheimer’s disease has hit the news this week. Eisai and Biogen have press-released top-line findings from a phase 3 trial of lecanemab. The results appear positive, showing a statistically significant slowing of cognitive decline measures over 18 months, compared with a placebo, as well as evidence that the drug reduces levels of amyloid protein in patients’ brains.